Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.895
Abstract: This study investigated the pharmacokinetics, pharmacodynamics, and safety of fotagliptin benzoate (fotagliptin), a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in Chinese patients with type 2 diabetes mellitus (T2DM). In a randomized, double‐blinded, placebo‐controlled study, 10 and 4… read more here.
Keywords: fotagliptin; dipeptidyl peptidase; type diabetes; pharmacokinetics pharmacodynamics ... See more keywords